Ting Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ting Xiao has a total of 318 co-authors. Here are the top co-authors by number of shared publications:
Yaru Wang
State Key Laboratory of Molecular Oncology Department of Etiology and Carcinogenesis National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
15 shared publicationsLin Feng
State Key Laboratory of Molecular Oncology Department of Etiology and Carcinogenesis National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
14 shared publicationsShujun Cheng
State Key Laboratory of Molecular Oncology Department of Etiology and Carcinogenesis National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China
11 shared publications- Shujun Cheng
College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150081, China
10 shared publications Yanning Gao
State Key Laboratory of Molecular Oncology, Beijing Key Laboratory for Carcinogenesis and Cancer Prevention, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China
8 shared publicationsHaiyang Li
State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
6 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Wiley in Advanced Science
- Vol. 13 (55) , e76482
Multi‐Omics Profiling of High‐Grade Serous Ovarian Cancer Reveals an Inflammation‐Related Lipid Metabolism Subtype Associated With Platinum Resistance
Ovarian cancer is the deadliest gynecological malignancy. The main obstacle in treating high‐grade serous ovarian cancer (HGSOC) is platinum resistance. The mechanistic interface between tumor metabolic reprogramming and platinum resistance remains undefined. We integrated proteomic and metabolomic profiling of 97 primary HGSOC tumors to map the molecular landscape. Unsupervised clustering identified three subtypes. Subtype 3 exhibited a higher platinum resistance rate (64.5%), as well as worse overall ( p = 0.001) and recurrence‐free ( p = 0.0001) survival. At the molecular level, both Subtypes 2 and 3 tumors displayed phenotypes of activated lipid metabolism. However, Subtype 3 tumors were unique, exhibiting potential divergence between lipid metabolism and bioenergetics. The arachidonic acid metabolism pathway was upregulated ( p = 2.0 × 10 −6 ), and the key enzyme cyclooxygenase‐2 (COX‐2) was overexpressed ( p < 0.001). Subtype 3 tumors exhibited an inflammation‐associated state with the highest infiltration of M2‐like macrophages ( p = 0.007). Single‐cell transcriptomics revealed increased expression of PTGS2 (encoding COX‐2, p = 0.001) and CD163 ( p < 2.2 × 10 −16 ) in macrophages from platinum‐resistant HGSOC. Multiplex immunofluorescence confirmed that platinum‐resistant tumors had a higher proportion of COX‐2 + cells in M2‐like macrophages ( p = 0.010). These findings define a high‐risk HGSOC subtype characterized by inflammation‐related lipid metabolism. This suggests targeting the arachidonic acid metabolism pathway as a way to overcome platinum resistance.
- 17 July 2026
- Published by Wiley in Advanced Science
- Vol. 13 (55) , e76482
Open AccessMulti‐Omics Profiling of High‐Grade Serous Ovarian Cancer Reveals an Inflammation‐Related Lipid Metabolism Subtype Associated With Platinum Resistance
Ovarian cancer is the deadliest gynecological malignancy. The main obstacle in treating high‐grade serous ovarian cancer (HGSOC) is platinum resistance. The mechanistic interface between tumor metabolic reprogramming and platinum resistance remains undefined. We integrated proteomic and metabolomic profiling of 97 primary HGSOC tumors to map the molecular landscape. Unsupervised clustering identified three subtypes. Subtype 3 exhibited a higher platinum resistance rate (64.5%), as well as worse overall ( p = 0.001) and recurrence‐free ( p = 0.0001) survival. At the molecular level, both Subtypes 2 and 3 tumors displayed phenotypes of activated lipid metabolism. However, Subtype 3 tumors were unique, exhibiting potential divergence between lipid metabolism and bioenergetics. The arachidonic acid metabolism pathway was upregulated ( p = 2.0 × 10 −6 ), and the key enzyme cyclooxygenase‐2 (COX‐2) was overexpressed ( p < 0.001). Subtype 3 tumors exhibited an inflammation‐associated state with the highest infiltration of M2‐like macrophages ( p = 0.007). Single‐cell transcriptomics revealed increased expression of PTGS2 (encoding COX‐2, p = 0.001) and CD163 ( p < 2.2 × 10 −16 ) in macrophages from platinum‐resistant HGSOC. Multiplex immunofluorescence confirmed that platinum‐resistant tumors had a higher proportion of COX‐2 + cells in M2‐like macrophages ( p = 0.010). These findings define a high‐risk HGSOC subtype characterized by inflammation‐related lipid metabolism. This suggests targeting the arachidonic acid metabolism pathway as a way to overcome platinum resistance.
- Open Access
Cross‐Level Regulatory Interactions Underlying Human Immune Aging
A comprehensive understanding of age‐related changes in the human immune system is critical for deciphering the mechanisms of immunosenescence. Although transcriptomic studies have described immune alterations during aging, investigations into the proteomic layer and integrated multi‐omics approaches remain scarce. Here, we performed multi‐omics sequencing on peripheral blood samples from 69 individuals aged 23–75 years. We identified widespread dysregulation of RNA splicing in aging immune cells, with exon skipping being the most prevalent splicing event, which was mainly enriched in protein regulation‐related processes. Notably, lncRNAs such as SNHG1 and RP1‐3J17.3 modulated the expression of splicing‐regulatory mRNAs and proteins in aging immune cells, thereby influencing the RNA splicing of downstream genes. Splicing dysregulation of genes including EIF4G1, a translation initiation factor, led to alterations in protein translation, modification, and degradation, ultimately reshaping protein profiles in aging leukocytes. These proteomic alterations in our data reflect a gradual weakening of T‐cell function during aging. Together, unlike previous studies that focused only on single molecular layers, our study elucidates the interconnected nature of molecular regulation within leukocytes during aging, uncovers cross‐level interactions and regulatory networks, and provides a comprehensive multi‐omics resource for understanding immune aging and identifying potential strategies to delay immunosenescence.
Open AccessCross‐Level Regulatory Interactions Underlying Human Immune Aging
A comprehensive understanding of age‐related changes in the human immune system is critical for deciphering the mechanisms of immunosenescence. Although transcriptomic studies have described immune alterations during aging, investigations into the proteomic layer and integrated multi‐omics approaches remain scarce. Here, we performed multi‐omics sequencing on peripheral blood samples from 69 individuals aged 23–75 years. We identified widespread dysregulation of RNA splicing in aging immune cells, with exon skipping being the most prevalent splicing event, which was mainly enriched in protein regulation‐related processes. Notably, lncRNAs such as SNHG1 and RP1‐3J17.3 modulated the expression of splicing‐regulatory mRNAs and proteins in aging immune cells, thereby influencing the RNA splicing of downstream genes. Splicing dysregulation of genes including EIF4G1, a translation initiation factor, led to alterations in protein translation, modification, and degradation, ultimately reshaping protein profiles in aging leukocytes. These proteomic alterations in our data reflect a gradual weakening of T‐cell function during aging. Together, unlike previous studies that focused only on single molecular layers, our study elucidates the interconnected nature of molecular regulation within leukocytes during aging, uncovers cross‐level interactions and regulatory networks, and provides a comprehensive multi‐omics resource for understanding immune aging and identifying potential strategies to delay immunosenescence.
- Open Access
- 4 June 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Proteomic stratification reveals immune metabolic heterogeneity in lung adenocarcinoma
Objective Lung Adenocarcinoma (LUAD) is a leading cause of cancer-related mortality worldwide. The relationship between metabolic reprogramming and immune infiltration has been identified as having a crucial impact on LUAD progression. The aim of this study is to achieve a deeper understanding of the interplay between the immune system and metabolism in the LUAD microenvironment. Methods A total of 213 treatment-naïve LUAD patients from two independent cohorts were enrolled. Using the proteomic data from one of the cohorts (n = 103), three molecular subtypes of LUAD were identified based on their immune signatures, clinical characteristics, metabolic reprogramming, and genomic features were analyzed. The data from the other cohort (n = 110) were used to validate the findings. Results Three subtypes with distinct immune environment (IM1-IM3) were identified in LUAD based on the proteomic dataset, each of which has distinctive clinical, immune, and metabolic characteristics. Among these subtypes, IM2, which has the highest immune infiltration and is more likely to benefit from immunotherapy. In contrast, IM3 was found to have the poorest prognosis, exhibits active hypoxia and glycosaminoglycan biosynthesis, and is thought to be associated with extracellular matrix remodeling and epithelial-mesenchymal transition activation. Additionally, the active glycosaminoglycan biosynthesis pathway in the IM3 subtype was associated with an immune-desert microenvironment. Conclusions This study presents the proteomic immune stratification of LUAD, revealing the possible link between immune cells and reprogramming of LUAD metabolisms, which may be a viable therapeutic strategy to improve LUAD immunotherapy.
- 4 June 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessProteomic stratification reveals immune metabolic heterogeneity in lung adenocarcinoma
Objective Lung Adenocarcinoma (LUAD) is a leading cause of cancer-related mortality worldwide. The relationship between metabolic reprogramming and immune infiltration has been identified as having a crucial impact on LUAD progression. The aim of this study is to achieve a deeper understanding of the interplay between the immune system and metabolism in the LUAD microenvironment. Methods A total of 213 treatment-naïve LUAD patients from two independent cohorts were enrolled. Using the proteomic data from one of the cohorts (n = 103), three molecular subtypes of LUAD were identified based on their immune signatures, clinical characteristics, metabolic reprogramming, and genomic features were analyzed. The data from the other cohort (n = 110) were used to validate the findings. Results Three subtypes with distinct immune environment (IM1-IM3) were identified in LUAD based on the proteomic dataset, each of which has distinctive clinical, immune, and metabolic characteristics. Among these subtypes, IM2, which has the highest immune infiltration and is more likely to benefit from immunotherapy. In contrast, IM3 was found to have the poorest prognosis, exhibits active hypoxia and glycosaminoglycan biosynthesis, and is thought to be associated with extracellular matrix remodeling and epithelial-mesenchymal transition activation. Additionally, the active glycosaminoglycan biosynthesis pathway in the IM3 subtype was associated with an immune-desert microenvironment. Conclusions This study presents the proteomic immune stratification of LUAD, revealing the possible link between immune cells and reprogramming of LUAD metabolisms, which may be a viable therapeutic strategy to improve LUAD immunotherapy.
- 22 May 2026
- Published by Elsevier in Laboratory Investigation
- Vol. 39 (7) , 101017
Multiomics Integration Identifies a Molecular Subtype of Intrahepatic Cholangiocarcinoma With Enhanced Benefit From Adjuvant Therapy
- 22 May 2026
- Published by Elsevier in Laboratory Investigation
- Vol. 39 (7) , 101017
Multiomics Integration Identifies a Molecular Subtype of Intrahepatic Cholangiocarcinoma With Enhanced Benefit From Adjuvant Therapy
- 20 April 2026
- Published by Springer Nature in MedScience
- Vol. 20 (2) , 1-18
Secretory leukocyte peptidase inhibitor as a dynamic radiotherapy response biomarker in esophageal squamous cell carcinoma
Esophageal cancer is the seventh leading cause of cancer-related deaths, with most cases diagnosed at locally advanced stages. Chemoradiotherapy is one of the most effective treatments for these patients. However, high rates of recurrence persist, highlighting the need for more reliable prognostic biomarkers. In this study, we identified immune-related prognostic genes through bulk (n = 119) and single-cell (n = 60) transcriptomic analyses. We then used Western blotting, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence to preliminarily investigate the potential biological functions of the candidate biomarker. The clinical prognostic utility of the candidate biomarker was validated in an independent cohort (n = 91) via ELISA of serum samples collected before and during chemoradiotherapy. The results showed that low expression of the secretory leukocyte peptidase inhibitor (SLPI) significantly correlated with tumor progression and poor prognosis. In epithelial cells, reduced SLPI expression was associated with decreased activation of differentiation-related pathways. Furthermore, SLPI expression levels were found to influence fibroblast phenotypes, with exogenous SLPI inhibiting the NF-κB pathway and restoring fibroblast quiescence. The results of ELISA showed that dynamic changes in serum SLPI levels during chemoradiotherapy serve as an independent prognostic factor. In conclusion, serum SLPI levels represent an easy-to-detect biomarker for dynamically monitoring the efficacy of chemoradiotherapy.
- 20 April 2026
- Published by Springer Nature in MedScience
- Vol. 20 (2) , 1-18
Secretory leukocyte peptidase inhibitor as a dynamic radiotherapy response biomarker in esophageal squamous cell carcinoma
Esophageal cancer is the seventh leading cause of cancer-related deaths, with most cases diagnosed at locally advanced stages. Chemoradiotherapy is one of the most effective treatments for these patients. However, high rates of recurrence persist, highlighting the need for more reliable prognostic biomarkers. In this study, we identified immune-related prognostic genes through bulk (n = 119) and single-cell (n = 60) transcriptomic analyses. We then used Western blotting, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence to preliminarily investigate the potential biological functions of the candidate biomarker. The clinical prognostic utility of the candidate biomarker was validated in an independent cohort (n = 91) via ELISA of serum samples collected before and during chemoradiotherapy. The results showed that low expression of the secretory leukocyte peptidase inhibitor (SLPI) significantly correlated with tumor progression and poor prognosis. In epithelial cells, reduced SLPI expression was associated with decreased activation of differentiation-related pathways. Furthermore, SLPI expression levels were found to influence fibroblast phenotypes, with exogenous SLPI inhibiting the NF-κB pathway and restoring fibroblast quiescence. The results of ELISA showed that dynamic changes in serum SLPI levels during chemoradiotherapy serve as an independent prognostic factor. In conclusion, serum SLPI levels represent an easy-to-detect biomarker for dynamically monitoring the efficacy of chemoradiotherapy.
- Open Access
- 26 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A metrological foundation for absolute transcriptomics using International System of Units-anchored calibrators
RNA-sequencing's conversion of molecules to reads is inconsistent. Experiment-to-experiment variations (systemic bias) create batch effects, while gene-to-gene variations (sequence-dependent bias) invalidate inter-gene comparisons, precluding a universal scale. This confines analysis to relative fold-changes, a metric unreliable across batches. We introduce TranScale: 100 biomimetic standards with SI-traceable concentrations certified by Isotope Dilution Mass Spectrometry. Co-processed within samples, they empirically characterize systemic and sequence-dependent biases, generating a library-specific calibration curve (R² > 0.97) to convert reads into absolute quantities. This approach reveals that consistent fold-changes can mask severe absolute errors, exposing systemic biases missed by conventional QC. Across laboratories, this calibration reduced median inter-lab CV from >85% to 7.9, outperforming the widely-used tool ComBat. By anchoring RNA-seq to the SI, our work establishes the metrological foundation for data interoperability and universal benchmarks, enabling absolute comparisons of SI-traceable quantities between any two genes.
- 26 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA metrological foundation for absolute transcriptomics using International System of Units-anchored calibrators
RNA-sequencing's conversion of molecules to reads is inconsistent. Experiment-to-experiment variations (systemic bias) create batch effects, while gene-to-gene variations (sequence-dependent bias) invalidate inter-gene comparisons, precluding a universal scale. This confines analysis to relative fold-changes, a metric unreliable across batches. We introduce TranScale: 100 biomimetic standards with SI-traceable concentrations certified by Isotope Dilution Mass Spectrometry. Co-processed within samples, they empirically characterize systemic and sequence-dependent biases, generating a library-specific calibration curve (R² > 0.97) to convert reads into absolute quantities. This approach reveals that consistent fold-changes can mask severe absolute errors, exposing systemic biases missed by conventional QC. Across laboratories, this calibration reduced median inter-lab CV from >85% to 7.9, outperforming the widely-used tool ComBat. By anchoring RNA-seq to the SI, our work establishes the metrological foundation for data interoperability and universal benchmarks, enabling absolute comparisons of SI-traceable quantities between any two genes.
- Open Access
Active Macropinocytosis, Lipid Catabolism, and Exhausting Immune Microenvironment of Ascites Tumor Cells Are Involved in Resistance to Platinum‐Based Therapy in Patients With High‐Grade Serous Ovarian Cancer
Platinum resistance remains a clinical challenge in ovarian cancer. Ascites represents an important mediator and a unique tumor microenvironment (TME) for invasion and metastasis. This study performed high‐resolution mass spectrometry (MS) on pre‐chemotherapy ascites cells from ovarian cancer patients. Integrating proteomic profiling, clinical data, and single‐cell analysis revealed that platinum‐resistant ascites displayed a distinct microenvironmental: the macropinocytosis‐related protein Src homology 3 domain‐containing YSC84‐like 1 (SH3YL1) was upregulated, whereas the immune‐activation marker CD44 was downregulated in resistant cases. Single‐cell analyses and pathway enrichment indicated immune exhaustion in resistant ascites, alongside enhanced macropinocytosis and lipid catabolism in tumor cells. Clinical data also showed that resistant ascites are lipid‐rich, with immunofluorescence plus flow cytometry confirming its association with immune exhaustion. Cellular experiments confirmed that SH3YL1‐mediated macropinocytosis promoted lipid uptake, and its inhibition partially restored cisplatin sensitivity. A combined model of immune exhaustion, macropinocytosis, and lipid catabolism suggests these ascites‐associated features could somewhat predict the platinum sensitivity in ovarian cancer tissues. We therefore propose the hypothesis that, in a lipid‐rich ascites microenvironment, immune exhaustion occurs while tumor cells activate macropinocytosis and lipid catabolism—forming a network of resistance mechanisms that may serve as potential predictive markers or intervention targets for platinum resistance.
Open AccessActive Macropinocytosis, Lipid Catabolism, and Exhausting Immune Microenvironment of Ascites Tumor Cells Are Involved in Resistance to Platinum‐Based Therapy in Patients With High‐Grade Serous Ovarian Cancer
Platinum resistance remains a clinical challenge in ovarian cancer. Ascites represents an important mediator and a unique tumor microenvironment (TME) for invasion and metastasis. This study performed high‐resolution mass spectrometry (MS) on pre‐chemotherapy ascites cells from ovarian cancer patients. Integrating proteomic profiling, clinical data, and single‐cell analysis revealed that platinum‐resistant ascites displayed a distinct microenvironmental: the macropinocytosis‐related protein Src homology 3 domain‐containing YSC84‐like 1 (SH3YL1) was upregulated, whereas the immune‐activation marker CD44 was downregulated in resistant cases. Single‐cell analyses and pathway enrichment indicated immune exhaustion in resistant ascites, alongside enhanced macropinocytosis and lipid catabolism in tumor cells. Clinical data also showed that resistant ascites are lipid‐rich, with immunofluorescence plus flow cytometry confirming its association with immune exhaustion. Cellular experiments confirmed that SH3YL1‐mediated macropinocytosis promoted lipid uptake, and its inhibition partially restored cisplatin sensitivity. A combined model of immune exhaustion, macropinocytosis, and lipid catabolism suggests these ascites‐associated features could somewhat predict the platinum sensitivity in ovarian cancer tissues. We therefore propose the hypothesis that, in a lipid‐rich ascites microenvironment, immune exhaustion occurs while tumor cells activate macropinocytosis and lipid catabolism—forming a network of resistance mechanisms that may serve as potential predictive markers or intervention targets for platinum resistance.
- 26 February 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 393, 114745
Losartan primes pancreatic tumors for effective exosome-biomimetic chemo-immunotherapy
- 26 February 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 393, 114745
Losartan primes pancreatic tumors for effective exosome-biomimetic chemo-immunotherapy
- Open Access
- 25 January 2026
- Published by Springer Nature in Cancer Cell International
- Vol. 26 (1)
TERT promoter C228T and C250T mutation detection combined with cytology in the diagnosis of urothelial carcinomas: a real-world cohort study in a Chinese population
Urothelial carcinoma (UC) is a malignancy of the urinary tract characterized by a high recurrence rate, imposing a substantial healthcare burden. Although
- 25 January 2026
- Published by Springer Nature in Cancer Cell International
- Vol. 26 (1)
Open AccessTERT promoter C228T and C250T mutation detection combined with cytology in the diagnosis of urothelial carcinomas: a real-world cohort study in a Chinese population
Urothelial carcinoma (UC) is a malignancy of the urinary tract characterized by a high recurrence rate, imposing a substantial healthcare burden. Although
- 21 January 2026
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 230, 112158
Senescent cancer-associated fibroblasts in cancer progression: From formation to therapeutic opportunities
- 21 January 2026
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 230, 112158
Senescent cancer-associated fibroblasts in cancer progression: From formation to therapeutic opportunities